Mp01-16 Molecular Drivers of Organotropism and Cisplatin Resistance in Germ Cell Tumors

You have accessJournal of UrologyPenile & Testicular Cancer I (MP01)1 May 2024MP01-16 MOLECULAR DRIVERS OF ORGANOTROPISM AND CISPLATIN RESISTANCE IN GERM CELL TUMORS Margaret F. Meagher, Yun Cheng Sawa, Liwei Jia, Frederick Millard, Harris Krause, Alex Farrell, Andrew Elliott, John Lafin, Christina Jamieson, Emmanuel Antonarakis, Anishka D'Souza, Krinio Giannikou, James Amatruda, Siamak Daneshmand, Rana McKay, Matthew Oberly, Chadi Nabhan, and Aditya Bagrodia Margaret F. MeagherMargaret F. Meagher , Yun Cheng SawaYun Cheng Sawa , Liwei JiaLiwei Jia , Frederick MillardFrederick Millard , Harris KrauseHarris Krause , Alex FarrellAlex Farrell , Andrew ElliottAndrew Elliott , John LafinJohn Lafin , Christina JamiesonChristina Jamieson , Emmanuel AntonarakisEmmanuel Antonarakis , Anishka D'SouzaAnishka D'Souza , Krinio GiannikouKrinio Giannikou , James AmatrudaJames Amatruda , Siamak DaneshmandSiamak Daneshmand , Rana McKayRana McKay , Matthew OberlyMatthew Oberly , Chadi NabhanChadi Nabhan , and Aditya BagrodiaAditya Bagrodia View All Author Informationhttps://doi.org/10.1097/01.JU.0001008660.87408.90.16AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Treatment failure in germ cell tumors (GCTs) can be driven by platinum resistance. We sought to characterize patterns of metastasis in germ cell tumors, and associate platinum resistance with primary versus metastatic GCTs. METHODS: GCT samples (N=138) collected between 2010 and 2022 were analyzed at Caris Life Sciences. A primary tumor (N=65) was defined as collected from the annotated primary. Metastatic tumors (N=73) were defined as any non-primary tumor biopsied from non-lymph node anatomic sites. Next-generation sequencing of DNA and RNA was performed. Frequency of platinum resistant alterations (PRAs: KRAS, TP53, KIT, MDM2) were compared between primary and metastatic sites. RESULTS: Primary tumor sites included: 7 intracranial (10.8%), 5 mediastinal (7.7%), 16 ovarian (24.6%), 37 testicular (56.9%). Metastatic sites included: 2 bone (2.7%), 11 brain (15.1%), 6 liver (8.2%), 5 lung (6.8%), 14 lymph node (19.2%), 4 mediastinum (5.5%), 12 peritoneum (16.4%), 1 testicle (1.4%), 18 (24.7%) non-bone/brain/liver visceral sites. Metastatic testicular primary accounted for 49 (67.1%) of metastatic specimens. We did note a significantly greater prevalence of KIT-Mt in primary (14.5%) versus metastatic (1.8%) tumors (p0.05). CONCLUSIONS: We present a large cohort of primary and metastatic germ cell tumors. We noted differing prevalence of PRAs between primary and metastatic sites, highlighting a potential mechanism by which cisplatin-based regimens fail. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e8 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Margaret F. Meagher More articles by this author Yun Cheng Sawa More articles by this author Liwei Jia More articles by this author Frederick Millard More articles by this author Harris Krause More articles by this author Alex Farrell More articles by this author Andrew Elliott More articles by this author John Lafin More articles by this author Christina Jamieson More articles by this author Emmanuel Antonarakis More articles by this author Anishka D'Souza More articles by this author Krinio Giannikou More articles by this author James Amatruda More articles by this author Siamak Daneshmand More articles by this author Rana McKay More articles by this author Matthew Oberly More articles by this author Chadi Nabhan More articles by this author Aditya Bagrodia More articles by this author Expand All Advertisement PDF downloadLoading ...